Literature DB >> 18286712

Levetiracetam has no acute effects on brain gamma-aminobutyric acid levels.

R Kuzniecky1, J Pan, A Burns, O Devinsky, H Hetherington.   

Abstract

OBJECTIVE: The mechanism of action of levetiracetam (LEV), an antiepileptic drug, is related to a novel binding site, SV2, but LEV acts on GABA-A receptors. The objective of the study described here was to determine if LEV modulates brain GABA in vivo.
METHODS: Concentrations of cerebral GABA and serum LEV were obtained in seven healthy individuals using 1H magnetic resonance spectroscopy at baseline and 3 and 6 hours following oral administration of 1 g of LEV.
RESULTS: Brain cerebral GABA acutely concentrations did not change from baseline.
CONCLUSION: The results indicate that LEV does not increase human cerebral GABA concentrations acutely in healthy individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18286712      PMCID: PMC3657745          DOI: 10.1016/j.yebeh.2007.09.020

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  13 in total

1.  Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose.

Authors:  O A Petroff; D L Rothman; K L Behar; R H Mattson
Journal:  Neurology       Date:  1996-05       Impact factor: 9.910

2.  Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.

Authors:  O A Petroff; F Hyder; D L Rothman; R H Mattson
Journal:  Epilepsia       Date:  2000-06       Impact factor: 5.864

Review 3.  Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs.

Authors:  H S White
Journal:  Epilepsia       Date:  1997       Impact factor: 5.864

4.  Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones.

Authors:  P Poulain; D G Margineanu
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

5.  Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults.

Authors:  Ruben Kuzniecky; S Ho; J Pan; R Martin; F Gilliam; E Faught; H Hetherington
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

6.  Topiramate increases cerebral GABA in healthy humans.

Authors:  R Kuzniecky; H Hetherington; S Ho; J Pan; R Martin; F Gilliam; J Hugg; E Faught
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

7.  Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T.

Authors:  H P Hetherington; G F Mason; J W Pan; S L Ponder; J T Vaughan; D B Twieg; G M Pohost
Journal:  Magn Reson Med       Date:  1994-11       Impact factor: 4.668

8.  The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy.

Authors:  O A Petroff; D L Rothman; K L Behar; D Lamoureux; R H Mattson
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

9.  The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents.

Authors:  J-M Rigo; G Hans; L Nguyen; V Rocher; S Belachew; B Malgrange; P Leprince; G Moonen; I Selak; A Matagne; H Klitgaard
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

10.  Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).

Authors:  Hermann Stefan; Ying Wang-Tilz; Elisabethe Pauli; Stephanie Dennhöfer; Alexandra Genow; Frank Kerling; Bogdan Lorber; Britta Fraunberger; Petra Halboni; Corinna Koebnick; Olaf Gefeller; Christian Tilz
Journal:  Epilepsia       Date:  2006-03       Impact factor: 5.864

View more
  2 in total

Review 1.  Clinical management of seizures in newborns : diagnosis and treatment.

Authors:  Linda G M van Rooij; Marcel P H van den Broek; Carin M A Rademaker; Linda S de Vries
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

2.  Transcriptomic analysis in a Drosophila model identifies previously implicated and novel pathways in the therapeutic mechanism in neuropsychiatric disorders.

Authors:  Priyanka Singh; Farhan Mohammad; Abhay Sharma
Journal:  Front Neurosci       Date:  2011-03-31       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.